MARKET

BOLD

BOLD

BOUNDLESS BIO INC
NASDAQ
1.520
-0.080
-5.00%
After Hours: 1.520 0 0.00% 18:48 03/26 EDT
OPEN
1.650
PREV CLOSE
1.600
HIGH
1.650
LOW
1.440
VOLUME
135.24K
TURNOVER
--
52 WEEK HIGH
15.24
52 WEEK LOW
1.440
MARKET CAP
33.90M
P/E (TTM)
-0.5537
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BOLD last week (0317-0321)?
Weekly Report · 2d ago
Weekly Report: what happened at BOLD last week (0310-0314)?
Weekly Report · 03/17 12:43
Weekly Report: what happened at BOLD last week (0303-0307)?
Weekly Report · 03/10 12:45
Weekly Report: what happened at BOLD last week (0224-0228)?
Weekly Report · 03/03 12:44
Weekly Report: what happened at BOLD last week (0217-0221)?
Weekly Report · 02/24 12:44
Weekly Report: what happened at BOLD last week (0210-0214)?
Weekly Report · 02/17 12:40
Weekly Report: what happened at BOLD last week (0203-0207)?
Weekly Report · 02/10 12:30
A Peek At AI Revolution In Mining: Promise Meets Peril
Seeking Alpha · 02/06 14:50
More
About BOLD
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells.

Webull offers Boundless Bio Inc stock information, including NASDAQ: BOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BOLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BOLD stock methods without spending real money on the virtual paper trading platform.